rs7840212

GWAS Catalog Trait Associations (6)

Genome-wide significant associations (p < 5×10⁻⁸) from the NHGRI-EBI GWAS Catalog.

eosinophil count

Allele T
OR
p 2.0e-92
N 583,850
Large GWAS
multi-ancestry
Verma A et al. Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. Science (new York, N.y.) 385(6706):eadj1182 (2024)
Allele T
OR 0.04
p 1.0e-39
N 447,366
Major Consortium StudyLarge GWAS
multi-ancestry
Sakaue S et al. A cross-population atlas of genetic associations for 220 human phenotypes. Nature Genetics 53(10):1415-1424 (2021)
Allele T
OR 0.03
p 2.0e-56
N 442,919
Large GWAS
multi-ancestry
Vuckovic D et al. The Polygenic and Monogenic Basis of Blood Traits and Diseases. Cell 182(5):1214-1231.e11 (2020)
Allele T
OR 0.04
p 4.0e-50
N 408,112
Large GWAS
European
Allele T
OR 0.03
p 9.0e-50
N 394,642
Large GWAS
European
Kachuri L et al. Genetic determinants of blood-cell traits influence susceptibility to childhood acute lymphoblastic leukemia. American Journal of Human Genetics 108(10):1823-1835 (2021)
Allele T
OR
p 8.0e-22
N 234,763
Large GWAS
European

eosinophil percentage of granulocytes

Allele T
OR 0.04
p 3.0e-31
N 170,536
Large GWAS
European

level of bone marrow proteoglycan in blood

Allele T
OR 0.05
p 6.0e-23
N 47,745
Large GWAS
European

body height

Allele T
OR 0.02
p 6.0e-16
N 455,180
Large GWAS
Hispanic or Latin American

proteoglycan 3 measurement

Pietzner M et al. Mapping the proteo-genomic convergence of human diseases. Science (new York, N.y.) 374(6569):eabj1541 (2021)
Allele T
OR 0.10
p 1.0e-12
N 10,708
Large GWAS
European

eosinophil percentage of leukocytes

Vuckovic D et al. The Polygenic and Monogenic Basis of Blood Traits and Diseases. Cell 182(5):1214-1231.e11 (2020)
Allele T
OR 0.02
p 2.0e-12
N 408,112
Large GWAS
European

This variant is in our database but has no known associations or PRS memberships yet.

Gene information from NCBI Gene. Variant classifications from ClinVar.

Community Wiki

No community notes yet for this variant. Sign in to start one.

Comments

Sign in to join the discussion.

Loading comments…